[HTML][HTML] The treatment of idiopathic pulmonary fibrosis
HV Woodcock, TM Maher - F1000prime reports, 2014 - ncbi.nlm.nih.gov
Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably fatal disease with a
median survival of less than three years from diagnosis. The last decade has seen an …
median survival of less than three years from diagnosis. The last decade has seen an …
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Rationale Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all
fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and …
fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and …
[HTML][HTML] A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells
CJC Johnston, DJ Smyth, RB Kodali, MPJ White… - Nature …, 2017 - nature.com
Helminth parasites defy immune exclusion through sophisticated evasion mechanisms,
including activation of host immunosuppressive regulatory T (Treg) cells. The mouse …
including activation of host immunosuppressive regulatory T (Treg) cells. The mouse …
[HTML][HTML] The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
HV Woodcock, JD Eley, D Guillotin, M Platé… - Nature …, 2019 - nature.com
Myofibroblasts are the key effector cells responsible for excessive extracellular matrix
deposition in multiple fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). The …
deposition in multiple fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). The …
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
HV Woodcock, PL Molyneaux… - Drug design, development …, 2013 - Taylor & Francis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no
clear etiology and a paucity of therapeutic options. Nintedanib (previously known as BIBF …
clear etiology and a paucity of therapeutic options. Nintedanib (previously known as BIBF …
mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-β1–induced collagen biosynthesis
B Selvarajah, I Azuelos, M Platé, D Guillotin… - Science …, 2019 - science.org
The differentiation of fibroblasts into a transient population of highly activated, extracellular
matrix (ECM)–producing myofibroblasts at sites of tissue injury is critical for normal tissue …
matrix (ECM)–producing myofibroblasts at sites of tissue injury is critical for normal tissue …
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
PT Lukey, SA Harrison, S Yang, Y Man… - European …, 2019 - Eur Respiratory Soc
Phosphatidylinositol 3-kinases (PI3Ks) and mammalian target of rapamycin (mTOR) play a
role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Omipalisib (GSK2126458) is …
role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Omipalisib (GSK2126458) is …
Author Correction: The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
HV Woodcock, JD Eley, D Guillotin, M Platé… - Nature …, 2020 - nature.com
The original version of this article omitted from the author list the 19th author Andrew Fisher,
who is from the Newcastle Fibrosis Research Group, Newcastle University Translational and …
who is from the Newcastle Fibrosis Research Group, Newcastle University Translational and …
A randomised, placebo-controlled, double-blind, repeat dose escalation study with omipalisib (GSK2126458) in patients with idiopathic pulmonary fibrosis (IPF)
TM Maher, P Bareille, MJ Costa, WA Fahy… - D14. IPF: MOVING …, 2017 - atsjournals.org
METHODS: Subjects were included if they had a diagnosis of IPF as defined by the
ATS/ERS consensus classification. Four cohorts of 4 subjects were administered twice daily …
ATS/ERS consensus classification. Four cohorts of 4 subjects were administered twice daily …
[PDF][PDF] Review of the British Thoracic Society Winter Meeting 2016, 7–9 December, London, UK
Review of the British Thoracic Society Winter Meeting 2016, 7–9 December, London, UK Page
1 Review of the British Thoracic Society Winter Meeting 2016, 7–9 December, London, UK …
1 Review of the British Thoracic Society Winter Meeting 2016, 7–9 December, London, UK …